Danaher Co. (NYSE:DHR) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors decreased its stake in Danaher Co. (NYSE:DHR - Free Report) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,899 shares of the conglomerate's stock after selling 3,364 shares during the period. Captrust Financial Advisors' holdings in Danaher were worth $28,608,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the second quarter worth about $25,000. nVerses Capital LLC purchased a new stake in shares of Danaher during the second quarter worth about $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the third quarter worth about $40,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Danaher during the second quarter worth about $51,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Up 0.4 %

Shares of NYSE DHR traded up $0.86 during trading on Friday, reaching $239.69. 1,931,402 shares of the stock were exchanged, compared to its average volume of 2,761,275. The business's 50-day moving average price is $254.59 and its 200 day moving average price is $259.44. Danaher Co. has a twelve month low of $215.68 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $173.12 billion, a price-to-earnings ratio of 45.74, a price-to-earnings-growth ratio of 4.39 and a beta of 0.85.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.59 billion. During the same period in the previous year, the company posted $2.02 earnings per share. The business's revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, equities analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher's payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on DHR shares. Wolfe Research upgraded shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Robert W. Baird lowered their target price on shares of Danaher from $278.00 to $277.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. Raymond James lowered their target price on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. Stephens restated an "overweight" rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Finally, UBS Group lowered their target price on shares of Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.